S&P 500   3,927.27 (+1.18%)
DOW   31,987.97 (+1.43%)
QQQ   322.79 (+0.41%)
AAPL   124.38 (-1.18%)
MSFT   234.09 (+0.35%)
FB   265.19 (-0.25%)
GOOGL   2,078.70 (+0.90%)
AMZN   3,147.15 (-1.48%)
TSLA   731.47 (+4.67%)
NVDA   574.08 (+1.48%)
BABA   249.82 (-1.16%)
CGC   35.48 (+0.48%)
GE   13.22 (+5.00%)
MU   91.18 (+3.34%)
NIO   51.01 (+3.87%)
AMD   86.07 (+1.57%)
T   29.40 (+0.75%)
F   12.38 (+6.54%)
ACB   11.44 (+2.05%)
DIS   197.95 (+0.44%)
BA   227.74 (+7.36%)
NFLX   552.34 (+1.13%)
BAC   36.42 (+2.53%)
S&P 500   3,927.27 (+1.18%)
DOW   31,987.97 (+1.43%)
QQQ   322.79 (+0.41%)
AAPL   124.38 (-1.18%)
MSFT   234.09 (+0.35%)
FB   265.19 (-0.25%)
GOOGL   2,078.70 (+0.90%)
AMZN   3,147.15 (-1.48%)
TSLA   731.47 (+4.67%)
NVDA   574.08 (+1.48%)
BABA   249.82 (-1.16%)
CGC   35.48 (+0.48%)
GE   13.22 (+5.00%)
MU   91.18 (+3.34%)
NIO   51.01 (+3.87%)
AMD   86.07 (+1.57%)
T   29.40 (+0.75%)
F   12.38 (+6.54%)
ACB   11.44 (+2.05%)
DIS   197.95 (+0.44%)
BA   227.74 (+7.36%)
NFLX   552.34 (+1.13%)
BAC   36.42 (+2.53%)
S&P 500   3,927.27 (+1.18%)
DOW   31,987.97 (+1.43%)
QQQ   322.79 (+0.41%)
AAPL   124.38 (-1.18%)
MSFT   234.09 (+0.35%)
FB   265.19 (-0.25%)
GOOGL   2,078.70 (+0.90%)
AMZN   3,147.15 (-1.48%)
TSLA   731.47 (+4.67%)
NVDA   574.08 (+1.48%)
BABA   249.82 (-1.16%)
CGC   35.48 (+0.48%)
GE   13.22 (+5.00%)
MU   91.18 (+3.34%)
NIO   51.01 (+3.87%)
AMD   86.07 (+1.57%)
T   29.40 (+0.75%)
F   12.38 (+6.54%)
ACB   11.44 (+2.05%)
DIS   197.95 (+0.44%)
BA   227.74 (+7.36%)
NFLX   552.34 (+1.13%)
BAC   36.42 (+2.53%)
S&P 500   3,927.27 (+1.18%)
DOW   31,987.97 (+1.43%)
QQQ   322.79 (+0.41%)
AAPL   124.38 (-1.18%)
MSFT   234.09 (+0.35%)
FB   265.19 (-0.25%)
GOOGL   2,078.70 (+0.90%)
AMZN   3,147.15 (-1.48%)
TSLA   731.47 (+4.67%)
NVDA   574.08 (+1.48%)
BABA   249.82 (-1.16%)
CGC   35.48 (+0.48%)
GE   13.22 (+5.00%)
MU   91.18 (+3.34%)
NIO   51.01 (+3.87%)
AMD   86.07 (+1.57%)
T   29.40 (+0.75%)
F   12.38 (+6.54%)
ACB   11.44 (+2.05%)
DIS   197.95 (+0.44%)
BA   227.74 (+7.36%)
NFLX   552.34 (+1.13%)
BAC   36.42 (+2.53%)
Log in
NYSE:JNJ

Johnson & Johnson Stock Forecast, Price & News

$163.54
+3.10 (+1.93 %)
(As of 02/24/2021 03:22 PM ET)
Add
Compare
Today's Range
$160.82
Now: $163.54
$164.39
50-Day Range
$157.89
MA: $163.06
$170.48
52-Week Range
$109.16
Now: $163.54
$173.65
Volume459,983 shs
Average Volume8.51 million shs
Market Capitalization$430.53 billion
P/E Ratio25.71
Dividend Yield2.50%
Beta0.7
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides orthopedic products; general surgery, biosurgical, endomechanical, and energy products; electrophysiology products to treat cardiovascular diseases; and vision care products, such as disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Johnson & Johnson logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP47816010
Phone732-524-0400
Employees132,200
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$82.06 billion
Cash Flow$11.93 per share
Book Value$22.60 per share

Profitability

Net Income$15.12 billion

Miscellaneous

Outstanding Shares2,632,543,000
Market Cap$430.53 billion
Next Earnings Date4/13/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

2.65 out of 5 stars

Medical Sector

2nd out of 1,958 stocks

Pharmaceutical Preparations Industry

1st out of 772 stocks

Analyst Opinion: 2.4Community Rank: 2.5Dividend Strength: 4.2Insider Behavior: 1.7Valuation: 2.5 5 -4 -3 -2 -1 -
$163.54
+3.10 (+1.93 %)
(As of 02/24/2021 03:22 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive JNJ News and Ratings via Email

Sign-up to receive the latest news and ratings for JNJ and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Johnson & Johnson (NYSE:JNJ) Frequently Asked Questions

Is Johnson & Johnson a buy right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Johnson & Johnson stock.
View analyst ratings for Johnson & Johnson
or view top-rated stocks.

What stocks does MarketBeat like better than Johnson & Johnson?

Wall Street analysts have given Johnson & Johnson a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Johnson & Johnson wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Johnson & Johnson's next earnings date?

Johnson & Johnson is scheduled to release its next quarterly earnings announcement on Tuesday, April 13th 2021.
View our earnings forecast for Johnson & Johnson
.

How were Johnson & Johnson's earnings last quarter?

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings data on Monday, January, 25th. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.82 by $0.04. The company had revenue of $22.50 million for the quarter, compared to analyst estimates of $21.62 billion. Johnson & Johnson had a trailing twelve-month return on equity of 34.64% and a net margin of 21.01%. Johnson & Johnson's quarterly revenue was up 8.7% on a year-over-year basis. During the same period last year, the company posted $1.88 EPS.
View Johnson & Johnson's earnings history
.

How has Johnson & Johnson's stock been impacted by COVID-19 (Coronavirus)?

Johnson & Johnson's stock was trading at $131.80 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, JNJ stock has increased by 24.2% and is now trading at $163.72.
View which stocks have been most impacted by COVID-19
.

How often does Johnson & Johnson pay dividends? What is the dividend yield for Johnson & Johnson?

Johnson & Johnson announced a quarterly dividend on Monday, January 4th. Investors of record on Tuesday, February 23rd will be paid a dividend of $1.01 per share on Tuesday, March 9th. This represents a $4.04 dividend on an annualized basis and a yield of 2.47%. The ex-dividend date of this dividend is Monday, February 22nd.
View Johnson & Johnson's dividend history
.

Is Johnson & Johnson a good dividend stock?

Johnson & Johnson pays an annual dividend of $4.04 per share and currently has a dividend yield of 2.50%. Johnson & Johnson has been increasing its dividend for 59 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Johnson & Johnson is 46.54%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Johnson & Johnson will have a dividend payout ratio of 45.44% next year. This indicates that Johnson & Johnson will be able to sustain or increase its dividend.
View Johnson & Johnson's dividend history.

What guidance has Johnson & Johnson issued on next quarter's earnings?

Johnson & Johnson issued an update on its FY21 earnings guidance on Tuesday, January, 26th. The company provided earnings per share (EPS) guidance of 9.25-$9.45 for the period, compared to the Thomson Reuters consensus EPS estimate of $9.00. The company issued revenue guidance of $88.8-$90.0 billion, compared to the consensus revenue estimate of $88.58 billion.

What price target have analysts set for JNJ?

15 brokers have issued 1 year target prices for Johnson & Johnson's shares. Their forecasts range from $155.00 to $200.00. On average, they expect Johnson & Johnson's share price to reach $178.93 in the next twelve months. This suggests a possible upside of 9.3% from the stock's current price.
View analysts' price targets for Johnson & Johnson
or view top-rated stocks among Wall Street analysts.

Who are Johnson & Johnson's key executives?

Johnson & Johnson's management team includes the following people:
  • Mr. Alex Gorsky, Chairman & CEO (Age 61, Pay $5.58M)
  • Mr. Joseph J. Wolk CPA, Exec. VP & CFO (Age 54, Pay $2.01M)
  • Dr. Paulus A. Stoffels, Chief Scientific Officer (Age 59, Pay $3.68M)
  • Mr. Joaquin Duato, Vice Chairman of Exec. Committee (Age 58, Pay $3.35M)
  • Ms. Jennifer L. Taubert, Exec. VP & Worldwide Chairman of Pharmaceuticals (Age 57, Pay $2.04M)
  • Mr. Robert J. Decker Jr., Controller & Chief Accounting Officer (Age 49)
  • Mr. James Swanson, Exec. VP & Global CIO
  • Mr. Christopher DelOrefice, VP of Investor Relations
  • Mr. Michael H. Ullmann, Exec. VP & Gen. Counsel (Age 62)
  • Ms. Ashley Watson, Chief Compliance Officer (Age 52)

What is Alex Gorsky's approval rating as Johnson & Johnson's CEO?

2,535 employees have rated Johnson & Johnson CEO Alex Gorsky on Glassdoor.com. Alex Gorsky has an approval rating of 94% among Johnson & Johnson's employees. This puts Alex Gorsky in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Johnson & Johnson's key competitors?

What other stocks do shareholders of Johnson & Johnson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Johnson & Johnson investors own include AT&T (T), Pfizer (PFE), Verizon Communications (VZ), The Walt Disney (DIS), NVIDIA (NVDA), Intel (INTC), JPMorgan Chase & Co. (JPM), Cisco Systems (CSCO), The Procter & Gamble (PG) and AbbVie (ABBV).

What is Johnson & Johnson's stock symbol?

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Who are Johnson & Johnson's major shareholders?

Johnson & Johnson's stock is owned by a variety of institutional and retail investors. Top institutional investors include Northern Trust Corp (1.24%), Bank of New York Mellon Corp (1.21%), Morgan Stanley (0.92%), Price T Rowe Associates Inc. MD (0.65%), Charles Schwab Investment Management Inc. (0.60%) and Nuveen Asset Management LLC (0.54%). Company insiders that own Johnson & Johnson stock include Ashley Mcevoy, Hubert Joly, Kathryn E Wengel, Marillyn A Hewson, Michael E Sneed and William D Perez.
View institutional ownership trends for Johnson & Johnson
.

Which major investors are selling Johnson & Johnson stock?

JNJ stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Bank Julius Baer & Co. Ltd Zurich, FMR LLC, Sumitomo Mitsui Trust Holdings Inc., Voloridge Investment Management LLC, Amundi Pioneer Asset Management Inc., Northern Trust Corp, and AJO LP. Company insiders that have sold Johnson & Johnson company stock in the last year include Ashley Mcevoy, Kathryn E Wengel, and Michael E Sneed.
View insider buying and selling activity for Johnson & Johnson
or view top insider-selling stocks.

Which major investors are buying Johnson & Johnson stock?

JNJ stock was bought by a variety of institutional investors in the last quarter, including Sanders Capital LLC, Morgan Stanley, Bank of New York Mellon Corp, Healthcare of Ontario Pension Plan Trust Fund, California Public Employees Retirement System, Price T Rowe Associates Inc. MD, Assenagon Asset Management S.A., and Alleghany Corp DE. Company insiders that have bought Johnson & Johnson stock in the last two years include Hubert Joly, Marillyn A Hewson, and William D Perez.
View insider buying and selling activity for Johnson & Johnson
or or view top insider-buying stocks.

How do I buy shares of Johnson & Johnson?

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Johnson & Johnson's stock price today?

One share of JNJ stock can currently be purchased for approximately $163.72.

How much money does Johnson & Johnson make?

Johnson & Johnson has a market capitalization of $431.00 billion and generates $82.06 billion in revenue each year. The company earns $15.12 billion in net income (profit) each year or $8.68 on an earnings per share basis.

How many employees does Johnson & Johnson have?

Johnson & Johnson employs 132,200 workers across the globe.

What is Johnson & Johnson's official website?

The official website for Johnson & Johnson is www.jnj.com.

Where are Johnson & Johnson's headquarters?

Johnson & Johnson is headquartered at ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933.

How can I contact Johnson & Johnson?

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.